
Dogwood Therapeutics, Inc (NASDAQ:DWTX – Free Report) – Equities research analysts at HC Wainwright boosted their FY2026 earnings estimates for Dogwood Therapeutics in a research note issued to investors on Friday, November 6th. HC Wainwright analyst S. Lee now expects that the company will post earnings of ($0.78) per share for the year, up from their prior forecast of ($0.80). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q3 2027 earnings at ($0.16) EPS, Q4 2027 earnings at ($0.16) EPS, FY2027 earnings at ($0.64) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at $0.55 EPS and FY2030 earnings at $1.32 EPS.
Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.10 million.
View Our Latest Research Report on Dogwood Therapeutics
Dogwood Therapeutics Trading Down 4.1%
NASDAQ DWTX opened at $1.18 on Tuesday. The business’s 50 day moving average is $1.45 and its two-hundred day moving average is $1.92. Dogwood Therapeutics has a 12-month low of $0.90 and a 12-month high of $7.04.
Dogwood Therapeutics Company Profile
Dogwood Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapies for diseases associated with viral activation. The company’s programs are designed to address conditions for which persistent or reactivated viral activity may contribute to symptoms and disease progression. Its lead investigational product, IMC-1, is an oral combination of the antiviral drug famciclovir and the anti-inflammatory drug celecoxib. The company has evaluated IMC-1 in fibromyalgia and has also investigated its potential use in other conditions, including symptoms associated with long COVID.
Read More
- Five stocks we like better than Dogwood Therapeutics
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Dogwood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dogwood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
